Sitagliptin Improves Glycemic Control and Protect Kidneys in Adolescents with Type 1 Diabetes, New Study Finds Medha Baranwal11 Nov 2024 8:30 AM ISTEgypt: A recent randomized controlled trial has demonstrated that sitagliptin, a DPP-4 inhibitor, significantly improves glycemic control and shows...
Add on SGLT-2 Inhibitors may help manage recurrence of nephrolithiasis and Gout in kidney stone patients, suggests study Medha Baranwal6 Nov 2024 3:30 AM ISTUSA: A recent study has shed light on the potential advantages of sodium-glucose cotransporter-2 (SGLT-2) inhibitors for patients experiencing...
Evaluating DPP4 inhibition and Bioequivalence of Vildagliptin 100mg SR ft Prof. Dr Aravinda Jagadeesha Dr. Nandita Mohan2 Jan 2023 10:45 AM IST Vildagliptin, a potent dipeptidyl peptidase IV inhibitor (DPP-4i), is usually administered twice daily to provide >90% inhibition of DPP-4 over...
Citing voglibose, sitagliptin incompatibility, CDSCO panel rejects Hetero Labs proposal for antidiabetic FDC drug Medical Dialogues Team13 March 2021 6:50 PM ISTNew Delhi: In a setback to Hetero Labs, the Subject Expert Committee (SEC) functional under the Central Drugs Standard Control Organization (CDSCO)...
Sitagliptin does not control blood sugar in paediatric patients with T2D, warns FDA MD Bureau17 Dec 2020 11:16 AM ISTUS Food and Drug Administration has recently approved labelling changes in Sitagliptin drug stating that sitagliptin and its combination with...
DPP-4 inhibitor therapy increases risk of bullous pemphigoid in diabetes patients: JAMA Medha Baranwal9 Aug 2020 2:56 PM ISTBoston, Massachusetts: The use of DPP-4 inhibitor therapy in type 2 diabetes patients (T2D) may lead to a higher risk of bullous pemphigoid...
